Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Moderate to Severe Hidradenitis Suppurativa
NCT06301256Not yet recruiting
- Sponsor
- Florida Academic Dermatology Center
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of tirzepatide in hidradenitis suppurativa (HS), sponsored by Florida Academic Dermatology Center. Primary endpoint: Hidradenitis Suppurativa Clinical Response 50% at 24 Weeks. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06301256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06301256.